155 related articles for article (PubMed ID: 11790188)
21. Trichomegaly of the eyelashes following treatment with cetuximab.
Bouché O; Brixi-Benmansour H; Bertin A; Perceau G; Lagarde S
Ann Oncol; 2005 Oct; 16(10):1711-2. PubMed ID: 15972283
[No Abstract] [Full Text] [Related]
22. [Adverse effects of new oncologic therapies].
Weisshaupt Ch; Budak K; Pestalozzi B
Praxis (Bern 1994); 2011 Jul; 100(15):885-91; quiz 890. PubMed ID: 21792802
[No Abstract] [Full Text] [Related]
23. Ecthymatous skin eruption during therapy with cetuximab.
Navarini AA; Kamacharova I; Kerl K; Donghi D; Cozzio A
Eur J Dermatol; 2011; 21(2):282-3. PubMed ID: 21489913
[No Abstract] [Full Text] [Related]
24. Papulopustular eruption after intravitreal bevacizumab (Avastin).
Amselem L; Diaz-Llopis M; Garcia-Delpech S; Montero J; Palomares P; Cervera E
Acta Ophthalmol; 2009 Feb; 87(1):110-1. PubMed ID: 18577190
[No Abstract] [Full Text] [Related]
25. Fixed drug eruption caused by articain.
Kleinhans M; Böer A; Kaufmann R; Boehncke WH
Allergy; 2004 Jan; 59(1):117. PubMed ID: 14674949
[No Abstract] [Full Text] [Related]
26. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Segaert S; Tabernero J; Chosidow O; Dirschka T; Elsner J; Mancini L; Maughan T; Morere JF; Santoro A; Sobrero A; Van Cutsem E; Layton A
J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
[TBL] [Abstract][Full Text] [Related]
27. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients.
Katzer K; Tietze J; Klein E; Heinemann V; Ruzicka T; Wollenberg A
Eur J Dermatol; 2010; 20(1):82-4. PubMed ID: 19797039
[TBL] [Abstract][Full Text] [Related]
28. Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab.
Monti M; Mancini LL; Ferrari B; Rahal D; Santoro A
J Clin Oncol; 2003 Dec; 21(24):4651-3. PubMed ID: 14673056
[No Abstract] [Full Text] [Related]
29. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.
Heun J; Holen K
Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202
[TBL] [Abstract][Full Text] [Related]
30. Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma.
Krishnan G; D'Silva K; Al-Janadi A
J Clin Oncol; 2008 May; 26(14):2406-8. PubMed ID: 18467734
[No Abstract] [Full Text] [Related]
31. Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors.
Cohen PR; Escudier SM; Kurzrock R
Am J Clin Dermatol; 2011 Feb; 12(1):63-7. PubMed ID: 20726623
[TBL] [Abstract][Full Text] [Related]
32. [Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid].
Wollenberg A; Moosmann N; Kroth J; Heinemann V; Klein E
Hautarzt; 2007 Jul; 58(7):615-8. PubMed ID: 17146641
[TBL] [Abstract][Full Text] [Related]
33. Drug-induced blaschkitis.
Brinkmeier T; Herbst RA; Schaller J; Kuegler K; Pirker C; Beiteke U; Grosshans E; Frosch PJ
Acta Derm Venereol; 2004; 84(4):314-5. PubMed ID: 15339081
[No Abstract] [Full Text] [Related]
34. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
35. Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
Dunsford J
Clin J Oncol Nurs; 2008 Jun; 12(3):405-7. PubMed ID: 18515238
[No Abstract] [Full Text] [Related]
36. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
Lacouture ME; Melosky BL
Skin Therapy Lett; 2007; 12(6):1-5. PubMed ID: 17762902
[TBL] [Abstract][Full Text] [Related]
37. Cetuximab in metastatic colorectal cancer.
Broadbridge VT; Karapetis CS; Price TJ
Expert Rev Anticancer Ther; 2012 May; 12(5):555-65. PubMed ID: 22594891
[TBL] [Abstract][Full Text] [Related]
38. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients.
Hertlein L; Lenhard M; Kirschenhofer A; Kahlert S; Mayr D; Burges A; Friese K
Arch Gynecol Obstet; 2011 Jan; 283(1):109-13. PubMed ID: 20180130
[TBL] [Abstract][Full Text] [Related]
39. Cetuximab-induced acneiform eruption and the response to isotretinoin.
Vezzoli P; Marzano AV; Onida F; Alessi E; Galassi B; Tomirotti M; Berti E
Acta Derm Venereol; 2008; 88(1):84-6. PubMed ID: 18176767
[No Abstract] [Full Text] [Related]
40. [Predictive factors of response to anti-EGFR treatments in colorectal cancer].
Lièvre A; Laurent-Puig P
Bull Cancer; 2008 Jan; 95(1):133-40. PubMed ID: 18230579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
